Omnipod Sales Soar, But Insulet's Outlook Cut Sparks Stock Selloff
Insulet (PODD) stock falls despite beating Q2 earnings as the company lowers its full-year 2026 revenue guidance. Get details here.
Share
Why It Matters
Insulet made more money than expected this quarter, which is good news. But the company said it won't make as much money for the rest of the year as it thought, which made investors worried.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.